Ability Biotherapeutics

Executive Summary

Ability Biotherapeutics is a preclinical-stage biotechnology company headquartered in Cambridge, MA, developing antibody-based therapies for immune and inflammatory disorders. Founded in 2019, the company leverages proprietary antibody engineering to target key pathways in autoimmunity and inflammation. With a focus on validated targets and an experienced management team, Ability is positioned to advance its pipeline toward clinical development. As a private preclinical firm, its near-term progress hinges on lead candidate selection, IND-enabling studies, and financing to support these activities.

Upcoming Catalysts (preview)

• Q3 2026Lead candidate nomination for IND-enabling studies80% success
• Q4 2026Initiation of IND-enabling toxicology studies70% success
• H2 2026Completion of Series A or B financing round60% success